We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Carboplatin, Abraxane, Avastin as Neoadjuvant Therapy for Her2-Negative Breast Cancer

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00723125
First Posted: July 28, 2008
Last Update Posted: August 22, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Yale University
Information provided by (Responsible Party):
William Sikov, Brown University
July 15, 2008
July 28, 2008
July 17, 2014
August 8, 2014
August 22, 2017
September 2008
May 15, 2014   (Final data collection date for primary outcome measure)
Pathological Complete Response Rates at Surgery [ Time Frame: at surgery approximately 5 months after initial treatment ]
To determine clinical & path. resp. rates, particularly pCR/near pCR rate,in HER2(-) stage IIA-IIIB Br. Ca with add. of Avastin 10 mg/kg q2weeks to either carboplatin/weekly Abraxane follow by ddAC (cohort1)or carboplatin/weekly Abraxane alone(cohort2). [ Time Frame: Prospective ]
Complete list of historical versions of study NCT00723125 on ClinicalTrials.gov Archive Site
Measure of Safety and Tolerability According to CTC Version 3.0 [ Time Frame: 2 years ]
To assess the toxicities of these regimens, and whether those toxicities affect treatment delivery, including complications of surgery [ Time Frame: 1 year ]
Not Provided
Not Provided
 
Carboplatin, Abraxane, Avastin as Neoadjuvant Therapy for Her2-Negative Breast Cancer
Q3week Carboplatin With Weekly Abraxaneä And Avastin + Subsequent Dose-Dense Ac With Avastin As Neoadjuvant Therapy In Resectable And Unresectable (Stage Iia-Iiib) Her2-Negative Breast Cancer
In the MDACC/BrUOG neoadjuvant trial with weekly paclitaxel followed by Fluorouracil Plus Doxorubicin and Cyclophosphamide (FAC), the pathologic complete response (pCR) rate in HER2(-) patients was 20%. The investigators' goal is to develop an induction chemotherapy regimen that will have a pCR rate above 30% in patients with HER2(-) disease. Based on a 1-sided 95% confidence interval using normal approximation with an expected pCR rate of at least 35%, approximately 28 patients are required for each cohort. With an assumed pCR rate of at least 35%, the investigators will have approximately 70% statistical power to conclude, with 90% certainty, that the pCR rate with the novel regimen exceeds 20%. The study will accrue approximately 60 patients in two cohorts with an inevaluable rate that does not exceed 10%.
See above brief summary
Interventional
Phase 2
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Breast Cancer
  • Drug: Abraxane
    Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks
  • Drug: Carboplatin
    Carboplatin at AUC 6 over 30 min IV weeks 1,4,7, and 10
  • Drug: Avastin
    Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 (in Cohort 2, omit dose of Avastin on week 10)
  • Experimental: Cohort 1

    Avastin 10 mg/kg IV over 90 minutes day -14

    Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10

    Avastin 10 mg/kg IV over 30-60 minutes cycles 1-3 (omit dose with cycle 4) Doxorubicin 60 mg/m2* and Cyclophosphamide 600 mg/m2 IV q2weeks x 4 cycles

    Definitive surgery

    Avastin 10 mg/kg IV over 30-60 minutes q2weeks x 34 weeks

    Interventions:
    • Drug: Abraxane
    • Drug: Carboplatin
    • Drug: Avastin
  • Experimental: Cohort 2

    Abraxane 100 mg/m2 IV over 30 minutes days -14 and -7

    Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks with Carboplatin at AUC 6 over 30 min IV and Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7

    Definitive surgery

    Avastin 10 mg/kg IV over 30-60 minutes and Doxorubicin 60 mg/m2* and Cyclophosphamide 600 mg/m2 IV q2weeks x 4 cycles followed by Avastin 10 mg/kg IV over 30-60 minutes q2weeks x 34 weeks OR Avastin 10 mg/kg IV over 30-60 minutes q2weeks x 42 weeks

    Interventions:
    • Drug: Abraxane
    • Drug: Carboplatin
    • Drug: Avastin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
60
May 15, 2014
May 15, 2014   (Final data collection date for primary outcome measure)

Eligibility criteria

Inclusion criteria:

  • Histologically documented adenocarcinoma of the breast
  • ANC > 1000 cells
  • Female; age > 18
  • Zubrod PS 0-1
  • Platelets > 100,000
  • Stage IIA-IIIB disease
  • Total bilirubin < 1.5 ULN
  • No evidence of any metastatic disease
  • Serum Creatinine < 1.5 gm/dl
  • No prior systemic therapy for breast cancer or Creat Cl > 30 ml/min
  • Not pregnant or lactating
  • Serum ALT < 2.0 ULN
  • ER, PR and HER2 status required
  • LVEF (MUGA/echo WNL)
  • No baseline > 2 neuropathy
  • Urine protein: creat ratio < 1.0
  • HER2-negative - either IHC 0-1+ or FISH ratio < 2.0
  • Hemoglobin > 9 gm/dl
  • (FISH testing is required for all HER2 2-3+ tumors by IHC)

Exclusion criteria:

  • No Histologically documented adenocarcinoma of the breast
  • No-ANC > 1000 cells
  • Female; age < 18
  • Zubrod PS > 0-1
  • Platelets < 100,000
  • Stage IV disease
  • Total bilirubin > 1.5 ULN
  • metastatic disease
  • Serum Creatinine > 1.5 gm/dl
  • prior systemic therapy for breast cancer or Creat Cl > 30 ml/min
  • pregnant or lactating
  • Serum ALT > 2.0 ULN baseline > 2 neuropathy
  • Urine protein: creat ratio >1.0
  • HER2-positive
  • Hemoglobin < 9 gm/dl
Sexes Eligible for Study: Female
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00723125
BrUOG-BR-211A
Yes
Not Provided
Not Provided
William Sikov, Brown University
William Sikov
Yale University
Principal Investigator: William Sikov, MD Brown University
Brown University
July 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP